A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

A Phase 2, Multicenter, Dose-Ranging Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

A Phase 2 study to evaluate the safety and efficacy of two different once daily doses VX-135 in combination with ribavirin in treatment-naïve subjects with chronic hepatitis C

Key Inclusion Criteria:

• Subjects (male and female) must be between the ages of 18 and 60 years at screening
• Subjects must have genotype 1 Chronic Hepatitis C
• Subjects must be treatment naïve
• Subjects must have laboratory values at screening within limits as specified by the protocol

Key Exclusion Criteria:

• Evidence of cirrhosis
• Female subjects who are pregnant or nursing or male subjects with a female partner of childbearing potential who is unwilling to adhere to the contraception requirements, is pregnant or nursing, or planning to become pregnant during the study
• Any other cause of significant liver disease in addition to hepatitis C
• Human immunodeficiency virus -1 or -2
• Diagnosis of or suspected hepatocellular carcinoma
• History of organ transplant, with the exception of corneal transplants and skin grafts